Close menu




June 5th, 2025 | 07:00 CEST

These ESG innovations really exist: Bayer, Deere & Company, Argo Living Soils

  • Agribusiness
  • fertilizer
  • Pharma
  • machinery
Photo credits: pexels.com

Sustainability is anything but boring: Companies such as Bayer and Deere & Company are scoring points with technological innovations that are more reminiscent of Elon Musk and SpaceX than specialists in seeds and agricultural machinery. The small Canadian agricultural company Argo Living Soils has even found a solution to completely revolutionize CO2-intensive processes in construction. We present the business models and take a look at the outlook for the three stocks.

time to read: 3 minutes | Author: Nico Popp
ISIN: BAYER AG NA O.N. | DE000BAY0017 , DEERE CO. DL 1 | US2441991054 , ARGO LIVING SOILS CORP | CA04018T3064

Table of contents:


    Deere & Company brings science fiction to the field

    When farmers use machines from Deere & Company to sow new seeds, the ExactShot™ system causes great amazement. Thanks to sensors and robot control, the system fertilizes with such precision that large amounts of fertilizer can be saved without having to accept lower yields. Almost even more revolutionary is the See & Spray technology: an AI-supported camera ensures that unwanted plants are treated with herbicide with pinpoint accuracy.** According to Deere itself, farmers have reduced their pesticide use by two-thirds with this technology, saving more than 8 million gallons of plant toxins. Precision approaches like those developed by Deere & Company reduce costs and protect soil, water, and endangered species.

    The smart farming systems are controlled via the John Deere Operations Center, a digital platform that provides real-time data on field conditions, machine utilization, and performance metrics. Farmers can monitor their operations via smartphone or PC and make data-driven decisions – from sowing time to harvest. This is not only efficient and reduces costs but is also sustainable. Analysts are giving Deere & Company's shares a good rating: Following the second quarter figures in May 2025, numerous banks have raised their price targets. Examples include JPMorgan (price target USD 540, Neutral), Barclays (USD 530, Overweight) and Raymond James (USD 560, Outperform).

    Bayer aims to become more innovative – Will acquisitions follow?

    Analyst opinions are more mixed when it comes to seed specialist Bayer – the consensus rating is "Hold." Those analysts who are more optimistic believe that the efficiency program launched last year will be successful. The core of the strategy is further innovation around sustainability: The Company plans to generate EUR 3.5 billion in additional revenue through new seed generations and more precise crop protection solutions that are more targeted and resource-efficient with the help of digital tools. Bayer plans to become as innovative as John Deere already is. Acquisitions also seem possible for the Leverkusen-based company.

    Argo Living Soils: Will this technology reduce our CO2 emissions?

    The Canadian company Argo Living Soils was founded with the aim of being a driver of innovation. The young company develops and produces organic products such as biofertilizers, worm compost, and other additives that make agricultural soils more fertile in a natural way. The business model focuses on the conversion of biomass into biochar. This biochar improves soil quality in agriculture and is considered a sustainable alternative to artificial fertilizers.

    But there is much more to the biochar produced by Argo Living Soils: the Company has developed a process to synthesize graphene from its biochar. This extremely stable carbon nanomaterial has a wide range of applications, such as an additive in asphalt to increase heat resistance or as a storage medium for hydrogen in energy systems. Argo Living Soils initially wants to use its graphene as an additive in construction and has already found partners for this. It recently entered into a research alliance with the technology company Graphene Leaders Canada with the aim of developing graphene nanoplatelets as an additive for ready-mixed concrete. The goals are to improve durability while reducing CO2 emissions in construction by around 20% through lower cement requirements. Argo Living Soils and its partners believe that this technology offers a significant lever for reducing CO2 emissions. According to the Karlsruhe Institute of Technology (KIT), concrete production is Germany's third-largest source of industrial greenhouse gas emissions.


    1,000% in one year: What is in it for investors?

    But does Argo Living Soils' approach also pay off for investors? Comparing the performance of Deere & Company and Bayer over a one-year period, the more innovative company John Deere is ahead with a return of 32.8% compared to Bayer, which lost 11% over the same period. The development of Argo Living Soils' share price, which rose by an incredible 1,061% over the course of a year, shows that the hunger for innovation is huge and that the market also offers excellent opportunities for small companies. Given its still low market capitalization of CAD 8.9 million and plans for the recently formed research alliance to deliver results by the end of the year, investors should keep an eye on ESG innovator Argo Living Soils. If the technology delivers what it promises, the Company is a takeover candidate – too many corporations are desperately looking for sustainable innovations.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by André Will-Laudien on July 29th, 2026 | 07:50 CEST

    Active Ingredients, Acquisitions and Spin-offs: Will Bayer, Novo Nordisk, BioNxt, or Evotec Become Top M&A Targets?

    • Biotechnology
    • Biotech
    • Pharma
    • Spin-Off
    • Takeover

    After years of consolidation, investors are asking: Will things start looking up again? The global life sciences sector is facing another massive wave of consolidation in 2026 as established pharmaceutical giants and agile biotech pioneers realign their businesses. Market dynamics remain high, but unfortunately, both sides are being exploited. So far, it has been predominantly speculative investors who are capitalizing on the current volatility. Following drastic share price losses and ongoing restructuring, the struggling Hamburg-based biotech company Evotec is increasingly in the crosshairs of financially strong acquirers seeking to acquire high-calibre drug discovery platforms at a bargain price. At the same time, BioNxt is attracting investor interest with its groundbreaking drug delivery systems and advanced clinical pipelines. Meanwhile, the market continues to speculate feverishly about a possible breakup or spin-off of individual divisions at the DAX-listed Bayer Group, which would massively increase its appeal to strategic buyers. On the other hand, Danish industry leader Novo Nordisk, driven by the sustained billion-dollar profits from its weight-loss portfolio, is acting as a financially powerful hunter in search of strategic acquisitions in the obesity and cardiovascular segments. For investors, this highly dynamic environment offers a rare opportunity to bet early on the year's hottest takeover candidates. What is the current status?

    Read

    Commented by Armin Schulz on July 29th, 2026 | 07:40 CEST

    Billion-Dollar Markets of Obesity, Oncology, and Neurology in Focus: Novo Nordisk, Vidac Pharma, and AbbVie

    • Pharma
    • Biotechnology
    • Neurology
    • Obesity

    The healthcare industry of the future is driven by three major megatrends: obesity, oncology, and neurology. While the market for cancer drugs is heading toward nearly USD 700 billion and Alzheimer's therapies are booming, the GLP-1 boom has only just begun and has replaced oncology as the largest driver of pipeline value. But not every company will benefit equally from this momentum. The key difference lies in strategic focus and the ability to translate scientific milestones into market success. We take a look at three companies today—Novo Nordisk, Vidac Pharma, and AbbVie—each of which embodies one of these areas.

    Read

    Commented by Nico Popp on July 23rd, 2026 | 07:50 CEST

    Panic in the Multi-Billion-Dollar Market: Novo Nordisk and Halozyme Therapeutics Face Headwinds—BioNxt Solutions Nears a Turning Point

    • Biotechnology
    • Biotech
    • Pharma
    • Innovations

    The global pharmaceutical market is worth hundreds of billions of dollars. Yet one of the industry's most surprising realities is that success increasingly depends not only on the active ingredient itself but also on how it is delivered. This does not refer to the cardboard box, but to the dosage form. Whenever patents expire, and blockbuster drugs face competition, innovative biotech companies seize the opportunity. New drug delivery technologies can transform well-known substances into more effective medicines, reduce side effects, and open up entirely new treatment options for patients. While established pharmaceutical giants spend vast sums defending market exclusivity, agile second-tier biotech companies are driving innovation through next-generation drug delivery platforms.

    Read